|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 婴幼儿卒中的处理:来自美国心脏协会卒中委员会和青少年心血管病委员会专门写作组的科学声明显示文摘目的:本声明旨在回顾有关儿童卒中的文献,为最佳的诊断和治疗提供推荐意见,供负责诊断和治疗婴儿、儿童和青少年脑血管病的医生使用。方法:写作组成员由美国心脏协会卒中委员会科学声明监督委员会任命,由多个不同领域的专家组成。应用美国心脏协会卒中委员会的证据分级标准对每条推荐意见进行分级。在经过小组成员审查后,草稿由4位同行评议专家和卒中委员会指导委员会成员审阅,并由美国心脏协会科学咨询和协调委员会批准。我们预计该声明需在4年内进行更新。结果:为镰状细胞病、烟雾病、颈一脑动脉夹层分离和心源性栓塞引起的缺血性卒中的预防提供循证推荐,同时为出血性卒中的评价和处理提供推荐意见。提出儿童使用肝素和华法林的剂量方案。另外,还为围产期卒中和儿童脑静脉窦血栓形成的评价和处理提供推荐。 | E.Steve Roach(著) Meredith R. Golomb(著) Robert Adams(著) Jose Biller(著) Stephen Daniels(著) Gabrielle deVeber(著) Donna Ferriero(著) Blaise V. Jones(著) Fenella J. Kirkham(著) R. Michael Scott(著) Edward R. Smith(著) 刘丽芳(译) 王胜男(译) 王伟(译) 林镇洲(译) 朱佳佳(译) 潘速跃(译) | 2008 | 国际脑血管病杂志2008，16，11： | 60 |
| 2 | 美国临床肿瘤学会IV期非小细胞肺癌化疗的临床实践指南更新显示文摘本文旨在为IV期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者,单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳。除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。 | Christopher G. AZZOLI Sherman Baker JR Sarah TEMIN William PAO Timothy ALIFF Julie BRAHMER David H. JOHNSON Janessa L. LASKIN Gregory MASTERS Daniel MILTON Luke NORDQUIST David G. PFISTER Steven PIANTADOSI Joan H. SCHILLER Reily SMITH Thomas J. SMITH John R. STRAWN David TRENT Giuseppe GIACCONE 丁燕(翻译) 南娟(翻译) 刘谦(翻译) 周清华(校对) 陈军(校对) | 2010 | 中国肺癌杂志2010，13，3： | 43 |
| 3 | 影响卒中死亡率下降的因素美国心脏协会/美国卒中协会的科学声明显示文摘背景和目的 美国的卒中死亡率自20世纪初以来一直呈下降趋势,尽管这种“下降”很受欢迎,但其原因尚不完全清楚.由于近年来卒中死亡率呈现出更为显著的加速下降趋势,卒中已从美国的第3位死亡原因下降至第4位.这促使人们对影响卒中发病风险和死亡率变化的相关因素进行详细评估.这份声明对有关卒中死亡率下降趋势的促进因素的研究证据进行回顾,并讨论了将来如何利用这些因素在卒中这一重大公共卫生问题的干预研究中发挥作用.方法 写作组成员由委员会主席和副主席根据其以前在相关领域的研究成果提名,并通过美国心脏协会(American Heart Association,AHA)卒中委员会的科学声明监督委员会和美国心脏协会手稿监督委员会批准.作者利用系统文献综述,参考公开发表的临床和流行病学研究、发病率和死亡率报告、临床与公共卫生指南、权威声明、个人文件以及专家意见,对相关证据进行总结并指出与当前知识水平的差距.所有写作组成员均有机会评论这份声明并批准其最终版本.这份声明经过AHA内部的广泛同行评议以及卒中委员会领导阶层和科学声明监督委员会的审查,然后获得AHA科学顾问与协调委员会的批准.结果 过去数十年间,在不同性别、所有种族/民族以及各个年龄组人群中都观察到卒中死亡率的下降,这体现出人群健康的重大进展.除了卒中对于总体寿命损失的影响减少外,在65岁以下人群中观察到的卒中死亡率显著下降体现了其所致潜在寿命损失年的减少.卒中死亡率的下降要归功于卒中发病率和病死率的降低.这些卒中转归的显著改善与心血管危险因素的控制和干预相一致.虽然很难计算出具体的归因危险度估计值,但始于20世纪70年代的血压控制措施似乎已对卒中死亡率的加速下降产生了最实质性的影响.尽管实施较晚,但糖尿病和血脂异常控制以及戒烟计划,特别是联合降压治疗,似乎同样促进了卒中死亡率的下降.远程医疗和卒中医疗体系也似乎具有强烈的潜在作用,但尚需足够长的时间来证明其对卒中死亡率下降的影响.其他因素也可能产生影响,但需要更多的研究来确定它们的作用.结论 卒中死亡率的下降是真实存在的,代表着公共卫生以及临床医学的巨大成功.卒中从第3位死亡原因下降至第4位是死亡率真实下降的结果,而并非由于慢性肺病死亡率上升所致,后者是目前在美国是第3位的死亡原因.有强烈的证据表明,卒中死亡率的下降可归功于以科学发现为基础、旨在降低卒中风险而执行的联合干预措施和项目,其中最有可能的是对高血压控制的改善.因此,对正在开展的干预项目进行的研究及其成果的应用已改善了人群健康.对一些积极的循证公共卫生项目以及临床干预措施的持续应用预期会进一步降低卒中死亡率. | Daniel T.Lackland Edward J.Roccella Anne F.Deutsch Myriam Fornage Mary G.George George Howard Brett M.Kissela Steven J.Kittner Judith H.Lichtman Lynda D. Lisabeth Lee H. Schwamm Eric E. Smith 高一鹭 陈政弘 王文志 | 2014 | 国际脑血管病杂志2014，22，5： | 41 |
| 4 | A community-derived classification for extant lycophytes and ferns显示文摘发展史长通知了蕨类植物分类。当我们推断进化的树的能力改善了,针对认出生来的组的分类变得逐渐地预兆、稳定。这里,我们为 lycophytes 和蕨纲植物提供一个现代、全面分类,在下面,利用一条基于社区的途径类水平。我们 monophyly 用作主要标准让 taxa,而且目的识别保存两个广泛地被接受的存在 taxa 和界限并且与我们蕨类植物发展史的理解一致。总共,这个分类对待一在 337 个类, 51 个家庭, 14 目,和二个班估计了 11 916 种类。这个分类没在 lycophyte 和蕨纲植物上作为最后的词被打算分类,而是当前的假设的概括陈述,源于最好的可得到的数据并且在问题由熟悉植物的那些大多数塑造了。我们希望它将在蕨类植物上为最近的文学的那些想要的参考用作一个资源发展史和分类,为指导未来调查的一个框架,和推进讲话的刺激。 | Eric Schuettpelz Harald Schneider Alan R. Smith Peter Hovenkamp Jefferson Prado Germinal Rouhan Alexandre Salino Michael Sundue Thafs Elias Almeida Barbara Parris Emily B. Sessa Ashley R. Field Andre Luis de Gasper Carl J. Rothfels Michael D. Windham Marcus Lehnert Benjamin Dauphin Atsushi Ebihara Samuli Lehtonen Pedro Bond Schwartsburd Jordan Metzgar Li-Bing Zhang Li-Yaung Kuo Patrick J. Brownsey Masahiro Kato Marcelo Daniel Arana Francine C. Assis Michael S. Barker David S. Barrington Ho-Ming Chang Yi-Han Chang Yi-Shan Chao Cheng-Wei Chen De-Kui Chen Wen-Liang Chiou Vinicius Antonio de Oliveira Dittrich Yi-Fan Duan Jean-Yves Dubuisson Donald R. Farrar Susan Fawcett Jose Maria Gabriel y Galan Luiz Armando de Araujo Goes-Neto Jason R. Grant Amanda L. Grusz Christopher Haufler Warren Hauk Hai He Sabine Hennequin Regina Yoshie Hirai Layne Huiet Michael Kessler Petra Korall Paulo H. Labiak Anders Larsson Blanca Leen Chun-Xiang Li Fay-Wei Li Melanie Link-Perez Hong-Mei Liu Ngan Thi Lu Esteban I. Meza-Torres Xin-Yuan Miao Robbin Moran Claudine Massi Mynssens Nathalie Nagalingum Benjamin Ollgaard Alison M. Paul Jovani B. de S. Pereira Leon R. Perrie Monica Ponce Tom A. Ranker Christian Schulz Wataru Shinohara Alexander Shmakov Erin M. Sigel Filipe Soares de Souza Lana da Silva Sylvestre Weston Testo Luz Amparo Triana-Moreno Chie Tsutsumi Hanna Tuomisto IvAn A. Valdespino Alejandra Vasco Raquel Stauffer Viveros Alan Weakley Ran Wei Stina Weststrand Paul G. Wolf George Yatskievych Xiao-Gang Xu Yue-Hong Yan Liang Zhang Xian-Chun Zhang Xin-Mao Zhou | 2016 | Journal of Systematics and Evolution2016，54，6： | 44 |
| 5 | Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil显示文摘AIM: To evaluate the methylation status of CDH1, FHIT, MTAP and PLAGL1 promoters and the association of these findings with clinico-pathological characteristics. METHODS: Methylation-specific PCR (MSP) assay was performed in 13 nonneoplastic gastric adenocarcinoma, 30 intestinal-type gastric adenocarcinoma and 35 diffuse- type gastric adenocarcinoma samples from individuals in Northern Brazil. Statistical analyses were performed using the chi-square or Fisher’s exact test to assess associations between methylation status and clinico- pathological characteristics. RESULTS: Hypermethylation frequencies of CDH1, FHIT, MTAP and PLAGL1 promoter were 98.7%, 53.9%, 23.1% and 29.5%, respectively. Hypermethylation of three or four genes revealed a significant association with diffuse-type gastric cancer compared with nonneoplastic cancer. A higher hypermethylation frequency wassignificantly associated with H pylori infection in gastric cancers, especially with diffuse-type. Cancer samples without lymph node metastasis showed a higher FHIT hypermethylation frequency. MTAP hypermethylation was associated with H pylori in gastric cancer samples, as well as with diffuse-type compared with intestinal-type. In diffuse-type, MTAP hypermethylation was associated with female gender. CONCLUSION: Our findings show differential gene methylation in tumoral tissue, which allows us to conclude that hypermethylation is associated with gastric carcinogenesis. MTAP promoter hypermethylation can be characterized as a marker of diffuse-type gastric cancer, especially in women and may help in diagnosis, prognosis and therapies. The H pylori infectious agent was present in 44.9% of the samples. This infection may be correlated with the carcinogenic process through the gene promoter hypermethylation, especially the MTAP promoter in diffuse-type. A higher H pylori infection in diffuse-type may be due to greater genetic predisposition. | Mariana Ferreira Leal Eleonidas Moura Lima Patrícia Natália Oliveira Silva Paulo Pimentel Assumpo Danielle Queiroz Calcagno Spencer Luiz Marques Payo Rommel Rodríguez Burbano Marília de Arruda Cardoso Smith | 2007 | World Journal of Gastroenterology2007，13，18： | 24 |
| 6 | DNA and histone methylation in gastric carcinogenesis显示文摘Epigenetic alterations contribute significantly to the development and progression of gastric cancer,one of the leading causes of cancer death worldwide.Epigenetics refers to the number of modifications of the chromatin structure that affect gene expression without altering the primary sequence of DNA,and these changes lead to transcriptional activation or silencing of the gene.Over the years,the study of epigenetic processes has increased,and novel therapeutic approaches that target DNA methylation and histone modifications have emerged.A greater understanding of epigenetics and the therapeutic potential of manipulating these processes is necessary for gastric cancer treatment.Here,we review recent research on the effects of aberrant DNA and histone methylation on the onset and progression of gastric tumors and the development of compounds that target enzymes that regulate the epigenome. | Danielle Queiroz Calcagno Carolina Oliveira Gigek Elizabeth Suchi Chen Rommel Rodriguez Burbano Marília de Arruda Cardoso Smith | 2013 | World Journal of Gastroenterology2013，19，8： | 14 |
| 7 | 将卒中纳入心血管风险预测工具美国心脏协会/美国卒中协会对医疗卫生专业人员的声明显示文摘背景和目的目前美国针对心血管事件风险预测以及一级和二级预防的指南声明均使用绝对风险估计值来识别血管事件高危患者以及可从特定干预措施中获益的患者。然而,这些指南并未明确地包括卒中患者。本指南对现有证据和争论进行概述以支持:(1)将卒中(尤其是动脉粥样硬化性卒中)患者纳入心血管病绝对风险增高的患者群体;(2)将卒中纳入血管性疾病风险预测工具的转归预测因素。方法和结果写作组成员由委员会联合主席基于先前在相关领域的研究成果来提名,并得到美国心脏协会(American Heart Association,AHA)卒中委员会科学声明监督委员会以及文稿监督委员会的批准。作者采用系统文献回顾(覆盖1980年1月至2010年3月期间的文献)并参考以往公布的指南、个人资料以及专家观点,以归纳现有证据,提出当前知识的不足,并根据AHA标准对适当的问题制定推荐意见。所有写作组成员均有机会对推荐意见进行评论并批准了最终版本。经广泛的AHA内部同行评议以及卒中委员会领导阶层和科学声明监督委员会的审阅后,最终获得AHA科学咨询和协调委员会的批准。将卒中患者(尤其是动脉粥样硬化性卒中患者)纳入冠状动脉和心血管病绝对高危人群的原因如下。首先,有证据显示,缺血性卒中患者发生致死性和非致死性心肌梗死或猝死的绝对风险增高,10年绝对风险≥20%,这一风险阈值已被一些指南用于定义冠状动脉疾病风险等危症。其次,纳入动脉粥样硬化性卒中的原因与纳入糖尿病、周围血管病、慢性肾脏病以及其他动脉粥样硬化性疾病的原因相同,尽管尚缺乏在所有人群或患者中风险增高的统一证据。再次,缺血性卒中的大动脉粥样硬化性卒中亚型与其他这些疾病的病理生理学机制相同。将卒中纳入高危因素将导致高危人群的数量扩大约10%。然而,由于卒中的异质性,尚不确定其他卒中亚型,包括出血性卒中以及非动脉粥样硬化性卒中亚型,是否应被视为具有相同水平的风险,因此有待进一步研究。鉴于卒中对残疾和死亡的影响、卒中与其他血管性疾病预防措施的相似性以及卒中在某些人群中较冠状动脉疾病更高的重要性,将卒中、心肌梗死和猝死纳入心血管事件风险预测工具的转归预测因素是合适的。美国以外的指南常常将卒中患者纳入心血管高危人群,并将卒中作为心脏终点的一个相关转归事件。结论动脉粥样硬化性卒中患者应被纳入会进一步发生冠状动脉粥样硬化事件的高危患者(10年≥20%)。是否应纳入非动脉粥样硬化卒中亚型尚不确定。对于一级预防,缺血性卒中应被纳入绝对风险评估方案的心血管疾病转归事件。将动脉粥样硬化性卒中作为一个高危因素或者更宽泛地将缺血性卒中视作一种转归事件纳入,可能对心血管病的预防具有重要意义,因为被评定为高危风险的患者数量将大幅增加。 | Daniel T. Lackland Mitchell S.V. Elkind Ralph D'Agostino Sr Mandip S. Dhamoon David C. Goff Jr Randall T. Higashida Leslie A. McClure Pamela H. Mitchell Ralph L. Sacco Cathy A. Sila Sidney C. Smith Jr David Tanne David L. Tirschwell Emmanuel Touze Lawrence R. Wechsler 4:~ 尤寿江(译) 于海龙(译) 刘慧慧(译) 张霞(译) 刘春风(译) | 2012 | 国际脑血管病杂志2012，20，11： | 13 |
| 8 | Role of mi RNAs and their potential to be useful as diagnostic and prognostic biomarkers in gastric cancer显示文摘Alterations in epigenetic control of gene expression play an important role in many diseases, including gastric cancer. Many studies have identified a large number of upregulated oncogenic mi RNAs and downregulated tumour-suppressor mi RNAs in this type of cancer. In this review, we provide an overview of the role of mi RNAs, pointing to their potential to be useful as diagnostic and/or prognostic biomarkers in gastric cancer. Moreover, we discuss the influence of polymorphisms and epigenetic modifications on mi RNA activity. | Kelly Cristina da Silva Oliveira Taíssa Maíra Thomaz Araújo Camila Inagaki Albuquerque Gabriela Alcantara Barata Carolina Oliveira Gigek Mariana Ferreira Leal Fernanda Wisnieski Fernando Augusto Rodrigues Mello Junior André Salim Khayat Paulo Pimentel de Assumpcao Rommel Mário Rodriguez Burbano Marília Cardoso Smith Danielle Queiroz Calcagno | 2016 | World Journal of Gastroenterology2016，22，35： | 11 |
| 9 | Interrelationship between chromosome 8 aneuploidy,C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma显示文摘AIM: To investigate chromosome 8 numerical aberra- tions, C-MYC oncogene alterations and its expression in gastric cancer and to correlate these findings with histo- pathological characteristics of gastric tumors. METHODS: Specimens were collected surgically from seven patients with gastric adenocarcinomas. Immu- nostaining for C-MYC and dual-color fluorescence in situ hybridization (FISH) for C-MYC gene and chromosome 8 centromere were performed. RESULTS: All the cases showed chromosome 8 aneu- ploidy and C-MYC amplification, in both the diffuse and intestinal histopathological types of Lauren. No significant difference (P < 0.05) was observed between the level ofchromosome 8 ploidy and the site, stage or histological type of the adenocarcinomas. C-MYC high amplification, like homogeneously stained regions (HSRs) and double minutes (DMs), was observed only in the intestinal-type. Structural rearrangement of C-MYC, like translocation, was observed only in the diffuse type. Regarding C-MYC gene, a significant difference (P < 0.05) was observed between the two histological types. The C-MYC protein was expressed in all the studied cases. In the intestinal- type the C-MYC immunoreactivity was localized only in the nucleus and in the diffuse type in the nucleus and cytoplasm. CONCLUSION: Distinct patterns of alterations between intestinal and diffuse types of gastric tumors support the hypothesis that these types follow different genetic path- ways. | Danielle Queiroz Calcagno Mariana Ferreira Leal Aline Damaceno Seabra Andre Salim Khayat Elizabeth Suchi Chen Samia Demachki Paulo Pimentel Assumpcao Mario Henrique Girao Faria Silvia Helena Barem Rabenhorst Márcia Valéria Pitombeira Ferreira Marília de Arruda Cardoso Smith Rommel Rodríguez Burbano | 2006 | World Journal of Gastroenterology2006，12，38： | 9 |
| 10 | MYC and gastric adenocarcinoma carcinogenesis显示文摘MYC is an oncogene involved in cell cycle regulation,cell growth arrest,cell adhesion,metabolism,ribosome biogenesis,protein synthesis,and mitochondrial function. It has been described as a key element of several carcinogenesis processes in humans. Many studies have shown an association between MYC deregulation and gastric cancer. MYC deregulation is also seen in gastric preneoplastic lesions and thus it may have a role in early gastric carcinogenesis. Several studies have suggested that amplification is the main mechanism of MYC deregulation in gastric cancer. In the present review,we focus on the deregulation of the MYC oncogene in gastric adenocarcinoma carcinogenesis,including its association with Helicobacter pylori (H pylori) and clinical applications. | Danielle Queiroz Calcagno Mariana Ferreira Leal Paulo Pimentel Assumpo Marília de Arruda Cardoso Smith Rommel Rodríguez Burbano | 2008 | World Journal of Gastroenterology2008，14，39： | 8 |
| 11 | Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology显示文摘 | Bernard Levin David A. Lieberman Beth McFarland Kimberly S. Andrews Durado Brooks John Bond Chiranjeev Dash Francis M. Giardiello Seth Glick David Johnson C. Daniel Johnson Theodore R. Levin Perry J. Pickhardt Douglas K. Rex Robert A. Smith Alan Thorson S | 2008 | Gastroenterology2008，，5： | 8 |
| 12 | Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement显示文摘 | Scott M. Grundy James I. Cleeman Stephen R. Daniels Karen A. Donato Robert H. Eckel Barry A. Franklin David J. Gordon Ronald M. Krauss Peter J. Savage Sidney C. Smith John A. Spertus Fernando Costa | 2005 | Circulation2005，，17： | 7 |
| 13 | Acute chylous ascites mimicking acute appendicitis in a patient with pancreatitis显示文摘We report a case of acute chylous peritonitis mimicking acute appendicitis in a man with acute on chronic pancreatitis. Pancreatitis, both acute and chronic, causing the development of acute chylous ascites and peritonitis has rarely been reported in the English literature. This is the fourth published case of acute chylous ascites mimicking acute appendicitis in the literature. | Emily K Smith Edmund Ek Daniel Croagh Lavinia A Spain Stephen Farrell | 2009 | World Journal of Gastroenterology2009，15，38： | 7 |
| 14 | Clinical implication of 14-3-3 epsilon expression in gastric cancer显示文摘AIM:To evaluate for the first time the protein and mRNA expression of 14-3-3εin gastric carcinogenesis.METHODS:14-3-3εprotein expression was determined by western blotting,and mRNA expression was examined by real-time quantitative RT-PCR in gastric tumors and their matched non-neoplastic gastric tissue samples.RESULTS:Authors observed a significant reduction of 14-3-3εprotein expression in gastric cancer(GC)samples compared to their matched non-neoplastic tissue.Reduced levels of 14-3-3εwere also associated with diffuse-type GC and early-onset of this pathology.Our data suggest that reduced 14-3-3εmay have a role in gastric carcinogenesis process.CONCLUSION:Our results reveal that the reduced 14-3-3εexpression in GC and investigation of 14-3-3ε interaction partners may help to elucidate the carcino-genesis process. | Mariana Ferreira Leal Danielle Queiroz Calcagno Smia Demachki Paulo Pimentel Assumpo Roger Chammas Rommel Rodríguez Burbano Marília de Arruda Cardoso Smith | 2012 | World Journal of Gastroenterology2012，18，13： | 6 |
| 15 | 代谢综合征的诊断和治疗——美国心脏协会/国立心肺血液研究所指南概要显示文摘 | Scott M. Grundy James I. Cleeman Stephen R. Daniels Karen A. Donato Robert H. Eckel Barry A.Franklin David J. Gordon Ronald M. Krauss Peter J. Savage Sidney C. Smith John A. Spertus Fernando Costa | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，2，4： | 5 |
| 16 | 美国西雅图地区城市边缘湖泊的富营养化显示文摘营养物污染和与之相关的淡水富营养化威胁着生态的完整性和影响湖泊给人类提供服务的功能。我们考察了美国华盛顿州西雅图地区人类住宅开发对湖泊富营养化程度的影响。我们调查了30个湖泊、测定了富营养化的三项指标叶绿素o浓度、磷浓度和不能被浮游动物消化的藻类的比例。我们依据湖岸家庭处理废物的方法给湖泊作了分类:有化粪池系统的湖泊、有下水道系统的湖泊和未开发湖泊。有化粪池系统的湖泊位于城乡结合部,而有下水道系统的湖泊则靠近市中心。有化粪池系统的湖泊,其磷和叶绿素α的水平较高,显示出富营养化程度比有下水道系统的湖泊和未开发的湖泊更高。这些结果说明化粪池系统是城乡结合部湖泊富营养化程度严重的主要原因。城乡结合部的湖泊为城市扩张提供了一个前瞻性管理的机会以使湖泊的富营养化尽可能减到最低程度。 | JonathanW.MooreDanielE.Schindler MarkD.Scheuerell Danielle Smith Jonathan Frodge 李康民 | 2003 | AMBIO-人类环境杂志2003，32，1： | 4 |
| 17 | Pushing the boundaries of diode-pumped solid-state lasers for high-energy applications显示文摘We report on the successful demonstration of a 150 J nanosecond pulsed cryogenic gas cooled,diode-pumped multi-slab Yb:YAG laser operating at 1 Hz.To the best of our knowledge,this is the highest energy ever recorded for a diodepumped laser system. | Saumyabrata Banerjee Paul Mason Jonathan Phillips Jodie Smith Thomas Butcher Jacob Spear Mariastefania De Vido Gary Quinn Danielle Clarke Klaus Ertel Cristina Hernez-Gomez Chris Edwards John Collier | 2020 | High Power Laser Science and Engineering2020，8，2： | 4 |
| 18 | AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute显示文摘 | Sidney C. Smith Jerilyn Allen Steven N. Blair Robert O. Bonow Lawrence M. Brass Gregg C. Fonarow Scott M. Grundy Loren Hiratzka Daniel Jones Harlan M. Krumholz Lori Mosca Richard C. Pasternak Thomas Pearson Marc A. Pfeffer Kathryn A. Taubert | 2006 | Circulation2006，，19： | 4 |
| 19 | Electron-driven heterogeneous catalytic synthesis of ammonia:Current states and perspective显示文摘Ammonia is the second most produced chemical worldwide that makes up 80%of nitrogen-based fertilisers,which have supported approximately 27%of the world’s population over the last century.The Haber–Bosch process,which is the main process for producing ammonia,is extremely energy intensive and consumes around 1%of the world’s energy.Additionally,it requires hydrogen gas as a reactant that is produced via steam reforming which emits carbon dioxide as a by-product.Over 500 million tonnes of ammonia are produced per year via industrial processes which required 3–5%of total natural gas consumption worldwide and also accounted for 2%global energy usage.Therefore,more sustainable processes,such as electrocatalysis and photocatalysis,using electrons and the transfer of protons has been investigated.This review covers the most state-of-the-art technologies used to produce ammonia via electrocatalysis and photocatalysis by comparing different electrolyte systems and electrocatalysts as well as discussing issues with these methods and possible solutions.In addition,substantial improvements to electrocatalysts and photocatalysts as well as methods to prevent both the promotion of the hydrogen evolution reaction and the decomposition of ammonia at higher temperatures are reviewed.Challenges and perspectives are discussed. | Ke Wang Daniel Smith Ying Zheng | 2018 | Carbon Resources Conversion2018，1，1： | 4 |
| 20 | 神经重症监护患者的液体治疗:ESICM专家共识及临床实践推荐显示文摘目的发布欧洲重症医学学会(European Society of Intensive Care Medicine, ESICM)关于神经重症监护患者液体治疗的专家共识和临床实践推荐意见。设计在2016年10月召开的ESICM LIVE 2016会议上召集了一个由22名国际专家组成的共识委员会,随后委员会成员通过电话会议和在线讨论制定本专家共识。方法回顾人群、干预、对比和结局(population, intervention,comparison, and outcomes, PICO)问题,根据需要进行更新并得到证据概要。本共识关注3个主要议题:(1)神经重症监护患者的液体复苏和维持;(2)高渗液体在颅内压控制中的应用;(3)蛛网膜下腔出血后迟发性脑缺血的液体管理。经过广泛的文献检索,应用推荐分级的评估、制订与评价(Gradingof Recommendations Assessment, Development and Evaluation, GRADE)系统原则评估证据质量(从高到极低),制定治疗推荐(强或弱),并在适用时发布最佳实践声明。基于文献和专家意见提供的综合证据,应用改良德尔菲方法(使用序贯方法以避免偏倚和误解)产生最终共识声明。结果最终共识包含总共32条声明,其中13条为强推荐,17条为弱推荐,另外2条声明未提供推荐意见。结论我们发布了一份关于神经重症监护患者液体治疗的共识声明和临床实践推荐。 | Mauro Oddo Daniele Poole Raimund Helbok Geert Meyfroidt Nino Stocchetti Pierre Bouzat Maurizio Cecconi Thomas Geeraerts Ignacio-Martin Loeches Herve Quintard Fabio Silvio Taccone Romergryko G. Geocadin Claude Hemphill Carole Ichai David Menon Jean-Francois Payen Anders Perner Martin Smith Jose Suarez Walter Videtta Elisa R. Zanier Giuseppe Citerio 何毅华(译) 常远(译) 王晓蔷(译) 潘速跃(译) | 2019 | 国际脑血管病杂志2019，27，2： | 4 |
您所在的机构暂未开通此部分的功能，请联系管理员